Although trastuzumab, pertuzumab and taxane combination was used as the standard treatment in HER2-positive metastatic disease in the first series, some patients can only use trastuzumab as anti-HER2 therapy due to treatment cost or toxicity. The gene discussed is ERBB2; the disease is metastatic neoplasm.